Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with advanced, unresectable or metastatic NRG1 fusion-positive non-small cell lung cancer or pancreatic adenocarcinoma that progressed on or after systemic therapy.
LAMPGEN ANALYSIS
Why it matters
The same HER2/HER3 bispecific targets a rare fusion in two tumor types; the label does not extend to every NRG1 fusion-positive cancer.
What research teams should watch
Coordinate fusion-capable molecular testing and specimen transfer so results are available when patients need another treatment.
PRIMARY RECORDS